Chirouze C,Alla F, FowlerVG Jr, Sexton DJ, Corey GR, ChuVH,WangA, Erpelding ML, Durante-Mangoni E, Fern ndez-Hidalgo N, Giannitsioti E, Hannan MM, Lejko-Zupanc T, Mir JM, Mu oz P, Murdoch DR, Tattevin P, Tribouilloy C, Hoen B; ICE Prospective Investigators. Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study. Clin Infect Dis. 2015;60:741 749. doi: 10.1093/cid/ciu871. 252. Karchmer AW, Bayer AS. Editorial commentary: surgical therapy for Staphylococcus aureus prosthetic valve endocarditis: proceed with cau- tion (caveat emptor). Clin Infect Dis. 2015;60:750 752. doi: 10.1093/ cid/ciu877. 253. Vikram HR, Buenconsejo J, Hasbun R, Quagliarello VJ. Impact of valve surgery on 6-month mortality in adults with complicated, left-sided native valve endocarditis: a propensity analysis. JAMA. 2003;290:3207 3214. doi: 10.1001/jama.290.24.3207. 254. Aksoy O, Sexton DJ, Wang A, Pappas PA, Kourany W, Chu V, Fowler VG Jr, Woods CW, Engemann JJ, Corey GR, Harding T, Cabell CH. Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis. 2007;44:364 372. doi: 10.1086/510583. 255. Cabell CH, Abrutyn E, Fowler VG Jr, Hoen B, Miro JM, Corey GR, Olaison L, Pappas P, Anstrom KJ, Stafford JA, Eykyn S, Habib G, Mestres CA, Wang A; International Collaboration on Endocarditis Merged Database (ICE-MD) Study Group Investigators. Use of surgery in patients with native valve infective endocarditis: results from the International Collaboration on Endocarditis Merged Database. Am Heart J. 2005;150:1092 1098. doi: 10.1016/j.ahj.2005.03.057. 256. Wang A, Pappas P, Anstrom KJ, Abrutyn E, Fowler VG Jr, Hoen B, Miro JM, Corey GR, Olaison L, Stafford JA, Mestres CA, Cabell CH; International Collaboration on Endocarditis Investigators. The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort. Am Heart J. 2005;150:1086 1091. doi: 10.1016/j.ahj.2005.01.023.


The use and effect of surgical therapy for prosthetic valve infective endocarditis: a propensity analysis of a multicenter, international cohort. Am Heart J. 2005;150:1086 1091. doi: 10.1016/j.ahj.2005.01.023. 257. van Walraven C, Davis D, Forster AJ, Wells GA. Time-dependent bias was common in survival analyses published in leading clini- cal journals. J Clin Epidemiol. 2004;57:672 682. doi: 10.1016/j. jclinepi.2003.12.008. 258. Tleyjeh IM, Ghomrawi HM, Steckelberg JM, Montori VM, Hoskin TL, Enders F, Huskins WC, Mookadam F, Wilson WR, Zimmerman V, Baddour LM. Conclusion about the association between valve surgery and mortality in an infective endocarditis cohort changed after adjusting for survivor bias. J Clin Epidemiol. 2010;63:130 135. doi: 10.1016/j. jclinepi.2008.06.022. 259. Lalani T, Chu VH, Park LP, Cecchi E, Corey GR, Durante-Mangoni E, Fowler VG Jr, Gordon D, Grossi P, Hannan M, Hoen B, Mu oz P, Rizk H, Kanj SS, Selton-Suty C, Sexton DJ, Spelman D, Ravasio V, Tripodi MF, WangA; International Collaboration on Endocarditis Prospective Cohort Study Investigators. In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis [published correction appears in JAMA Intern Med. 2013;173:1846]. JAMA Intern Med. 2013;173:1495 1504. doi: 10.1001/jamainternmed. 2013.8203. 260. Gaca JG, Sheng S, Daneshmand MA, O Brien S, Rankin JS, Brennan JM, Hughes GC, Glower DD, Gammie JS, Smith PK. Outcomes for endocarditis surgery in North America: a simplified risk scoring sys- tem. J Thorac Cardiovasc Surg. 2011;141:98 106.e1 e2. doi: 10.1016/j. jtcvs.2010.09.016. 261. Botelho-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, Collart F, Riberi A, Habib G, Raoult D. Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med. 2009;169:1290 1298. doi: 10.1001/ archinternmed.2009.192. 262. Tleyjeh IM, Steckelberg JM, Georgescu G, Ghomrawi HM, Hoskin TL, Enders FB, Mookadam F, Huskins WC, Wilson WR, Baddour LM.


Tleyjeh IM, Steckelberg JM, Georgescu G, Ghomrawi HM, Hoskin TL, Enders FB, Mookadam F, Huskins WC, Wilson WR, Baddour LM. The association between the timing of valve surgery and 6-month mortal- ity in left-sided infective endocarditis [published correction appears hrt.2007.118968. 263. Musci M, Siniawski H, Pasic M, Grauhan O, Weng Y, Meyer R, Yankah CA, Hetzer R. Surgical treatment of right-sided active infective endocar- ditis with or without involvement of the left heart: 20-year single center experience. Eur J Cardiothorac Surg. 2007;32:118 125. doi: 10.1016/j. ejcts.2007.02.034. 264. Akinosoglou K, Apostolakis E, Koutsogiannis N, Leivaditis V, Gogos CA. Right-sided infective endocarditis: surgical management. Eur J Cardiothorac Surg. 2012;42:470 479. doi: 10.1093/ejcts/ezs084. 265. Maruyama M, Kuriyama Y, Sawada T, Yamaguchi T, Fujita T, Omae T. Brain damage after open heart surgery in patients with acute cardioem- bolic stroke. Stroke. 1989;20:1305 1310. 266. GillinovAM, Shah RV, Curtis WE, Stuart RS, Cameron DE, Baumgartner WA, Greene PS. Valve replacement in patients with endocarditis and acute neurologic deficit. Ann Thorac Surg. 1996;61:1125 1129. 267. Eishi K, Kawazoe K, Kuriyama Y, Kitoh Y, Kawashima Y, Omae T. Surgical management of infective endocarditis associated with cere- bral complications: multi-center retrospective study in Japan. J Thorac Cardiovasc Surg. 1995;110:1745 1755. 268. Cooper HA, Thompson EC, Laureno R, Fuisz A, Mark AS, Lin M, Goldstein SA. Subclinical brain embolization in left-sided infective endocarditis: results from the Evaluation by MRI of the Brains of Patients With Left-Sided Intracardiac Solid Masses (EMBOLISM) pilot study. Circulation. 2009;120:585 591. doi: 10.1161/CIRCULATIONAHA. 108.834432. 269. Hosono M, SasakiY, Hirai H, Sakaguchi M, NakahiraA, Seo H, Morisaki A, Suehiro S. Considerations in timing of surgical intervention for infec- tive endocarditis with cerebrovascular complications. J Heart Valve Dis. 2010;19:321 325. 270.


Hosono M, SasakiY, Hirai H, Sakaguchi M, NakahiraA, Seo H, Morisaki A, Suehiro S. Considerations in timing of surgical intervention for infec- tive endocarditis with cerebrovascular complications. J Heart Valve Dis. 2010;19:321 325. 270. Ruttmann E, Willeit J, Ulmer H, Chevtchik O, H fer D, Poewe W, Laufer G, M ller LC. Neurological outcome of septic cardioembolic stroke after infective endocarditis. Stroke. 2006;37:2094 2099. doi: 10.1161/01. STR.0000229894.28591.3f. 271. Snygg-Martin U, Gustafsson L, Rosengren L, Alsi A, Ackerholm P, Andersson R, Olaison L. Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers. Clin Infect Dis. 2008;47:23 30. doi: 10.1086/588663. 272. Thuny F, Avierinos JF, Tribouilloy C, Giorgi R, Casalta JP, Milandre L, Brahim A, Nadji G, Riberi A, Collart F, Renard S, Raoult D, Habib G. Impact of cerebrovascular complications on mortality and neuro- logic outcome during infective endocarditis: a prospective multicen- tre study. Eur Heart J. 2007;28:1155 1161. doi: 10.1093/eurheartj/ ehm005. 273. Barsic B, Dickerman S, Krajinovic V, Pappas P, Altclas J, Carosi G, Casab JH, Chu VH, Delahaye F, Edathodu J, Fortes CQ, Olaison L, Pangercic A, Patel M, Rudez I, Tamin SS, Vincelj J, Bayer AS, Wang A; International Collaboration on Endocarditis Prospective Cohort Study Investigators. Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis. 2013;56:209 217. doi: 10.1093/cid/cis878. R, Noureddine M, PlataA, Lomas JM, G lvez-Acebal J, Hidalgo-Tenorio C, Ru z-Morales J, Mart nez-Marcos FJ, Reguera JM, de la Torre-Lima J, deAlarc n Gonz lezA; Group for the Study of Cardiovascular Infections of the Andalusian Society of Infectious Diseases; Spanish Network for Research in Infectious Diseases.


R, Noureddine M, PlataA, Lomas JM, G lvez-Acebal J, Hidalgo-Tenorio C, Ru z-Morales J, Mart nez-Marcos FJ, Reguera JM, de la Torre-Lima J, deAlarc n Gonz lezA; Group for the Study of Cardiovascular Infections of the Andalusian Society of Infectious Diseases; Spanish Network for Research in Infectious Diseases. Neurological complications of infec- tive endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation. 2013;127:2272 2284. doi: 10.1161/CIRCULATIONAHA.112.000813. 275. Lutas EM, Roberts RB, Devereux RB, Prieto LM. Relation between the presence of echocardiographic vegetations and the complication rate in infective endocarditis. Am Heart J. 1986;112:107 113. 276. De Castro S, Magni G, Beni S, Cartoni D, Fiorelli M, Venditti M, Schwartz SL, Fedele F, Pandian NG. Role of transthoracic and trans- esophageal echocardiography in predicting embolic events in patients with active infective endocarditis involving native cardiac valves. Am J Cardiol. 1997;80:1030 1034. 277. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch Intern Med. 2000;160:2781 2787. 278. Vilacosta I, Graupner C, San Rom n JA, Sarri C, Ronderos R, Fern ndez C, Mancini L, Sanz O, Sanmart n JV, Stoermann W. Risk of embolization after institution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol. 2002;39:1489 1495. 279. Deleted in proof. 280. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, Doco-Lecompte T, Eisen DP, Fortes CQ, Fowler VG Jr, Lerakis S, Miro JM, Pappas P, Peterson GE, Rubinstein E, Sexton DJ, Suter F, Tornos P, Verhagen DW, Cabell CH; ICE Investigators. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J. 2007;154:1086 1094. doi: 10.1016/j. ahj.2007.07.023.


The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J. 2007;154:1086 1094. doi: 10.1016/j. ahj.2007.07.023. 281. Thuny F, Di Salvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, Casalta JP, Gouvernet J, Derumeaux G, Iarussi D, Ambrosi P, Calabr R, Calabro R, Riberi A, Collart F, Metras D, Lepidi H, Raoult D, Harle JR, Weiller PJ, Cohen A, Habib G. Risk of embolism and death in infec- tive endocarditis: prognostic value of echocardiography: a prospec- tive multicenter study [published correction appears in Circulation. CIRCULATIONAHA.104.493155. 282. Alsip SG, Blackstone EH, Kirklin JW, Cobbs CG. Indications for car- diac surgery in patients with active infective endocarditis. Am J Med. 1985;78:138 148. Baddour et al Infective Endocarditis in Adults 1485 283. Di Salvo G, Habib G, Pergola V, Avierinos JF, Philip E, Casalta JP, Vailloud JM, Derumeaux G, Gouvernet J, Ambrosi P, Lambert M, Ferracci A, Raoult D, Luccioni R. Echocardiography predicts embolic events in infective endocarditis. J Am Coll Cardiol. 2001;37:1069 1076. 284. Chu VH, Cabell CH, Benjamin DK Jr, Kuniholm EF, Fowler VG Jr, Engemann J, Sexton DJ, Corey GR, Wang A. Early predictors of in-hos- pital death in infective endocarditis. Circulation. 2004;109:1745 1749. doi: 10.1161/01.CIR.0000124719.61827.7F. 285. Salem DN, Daudelin HD, Levine HJ, Pauker SG, Eckman MH, Riff J. Antithrombotic therapy in valvular heart disease. Chest. 2001;119(suppl):207S 219S. 286. Tornos P, Almirante B, Mirabet S, Permanyer G, Pahissa A, Soler-Soler J. Infective endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant therapy. Arch Intern Med. 1999;159:473 475. 287. Kupferwasser LI, Yeaman MR, Nast CC, Kupferwasser D, Xiong YQ, Palma M, Cheung AL, Bayer AS. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin Invest.


Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin Invest. 2003;112:222 233. doi: 10.1172/ JCI16876. 288. Chan KL, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek MA, Robinson TI, Moher D; Investigators of the Multicenter Aspirin Study in Infective Endocarditis. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol. 2003;42:775 780. 289. Kupferwasser LI,Yeaman MR, Shapiro SM, Nast CC, Sullam PM, Filler SG, Bayer AS. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation. 1999;99:2791 2797. 290. Anavekar NS, Tleyjeh IM, Anavekar NS, Mirzoyev Z, Steckelberg JM, Haddad C, Khandaker MH,WilsonWR, Chandrasekaran K, Baddour LM. Impact of prior antiplatelet therapy on risk of embolism in infective endo- carditis [published correction appears in Clin Infect Dis. 2007;44:1398]. Clin Infect Dis. 2007;44:1180 1186. doi: 10.1086/513197. 291. Chan KL, Tam J, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek M, Robinson T, Williams K. Effect of long-term aspirin use on embolic events in infective endocarditis. Clin Infect Dis. 2008;46:37 41. doi: 10.1086/524021. 292. Eisen DP, Corey GR, McBryde ES, Fowler VG Jr, Miro JM, Cabell CH, Street AC, Paiva MG, Ionac A, Tan RS, Tribouilloy C, Pachirat O, Jones SB, Chipigina N, Naber C, Pan A, Ravasio V, Gattringer R, Chu VH, Bayer AS; ICE Investigators. Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiv- ing acetyl-salicylic acid. J Infect. 2009;58:332 338. doi: 10.1016/j. jinf.2009.03.006. 293. Pepin J, Tremblay V, Bechard D, Rodier F, Walker C, Dufresne D, Lafontaine A, Li N, Lacroix C, Lanthier L. Chronic antiplatelet therapy and mortality among patients with infective endocarditis. Clin Microbiol Infect.


Pepin J, Tremblay V, Bechard D, Rodier F, Walker C, Dufresne D, Lafontaine A, Li N, Lacroix C, Lanthier L. Chronic antiplatelet therapy and mortality among patients with infective endocarditis. Clin Microbiol Infect. 2009;15:193 199. doi: 10.1111/j.1469-0691. 2008.02665.x. 294. Snygg-Martin U, Rasmussen RV, Hassager C, Bruun NE, Andersson R, Olaison L. The relationship between cerebrovascular complica- tions and previously established use of antiplatelet therapy in left- sided infective endocarditis. Scand J Infect Dis. 2011;43:899 904. doi: 10.3109/00365548.2011.603742. 295. Anavekar NS, Schultz JC, De Sa DD, Thomas JM, Lahr BD, Tleyjeh IM, Steckelberg JM, Wilson WR, Baddour LM. Modifiers of symptomatic embolic risk in infective endocarditis [published correction appears in Mayo Clin Proc. 2012;87:309]. Mayo Clin Proc. 2011;86:1068 1074. doi: 10.4065/mcp.2011.0111. 296. Omari B, Shapiro S, Ginzton L, Robertson JM, Ward J, Nelson RJ, Bayer AS. Predictive risk factors for periannular extension of native valve endocarditis: clinical and echocardiographic analyses. Chest. 1989;96:1273 1279. 297. Middlemost S, Wisenbaugh T, Meyerowitz C, Teeger S, Essop R, Skoularigis J, Cronje S, Sareli P. A case for early surgery in native left- sided endocarditis complicated by heart failure: results in 203 patients. J Am Coll Cardiol. 1991;18:663 667. 298. Blumberg EA, Karalis DA, Chandrasekaran K, Wahl JM, Vilaro J, Covalesky VA, Mintz GS. Endocarditis-associated paravalvular abscesses: do clinical parameters predict the presence of abscess? Chest. 1995;107:898 903. 299. Becher H, Hanrath P, Bleifeld W, Bleese N. Correlation of echocardio- graphic and surgical findings in acute bacterial endocarditis. Eur Heart J. 1984;5(suppl C):67 70. 300. Arnett EN, Roberts WC. Prosthetic valve endocarditis: clinicopathologic analysis of 22 necropsy patients with comparison observations in 74 nec- ropsy patients with active infective endocarditis involving natural left- sided cardiac valves. Am J Cardiol. 1976;38:281 292. 301. Fernicola DJ, Roberts WC.


Am J Cardiol. 1976;38:281 292. 301. Fernicola DJ, Roberts WC. Frequency of ring abscess and cuspal infec- tion in active infective endocarditis involving bioprosthetic valves. Am J Cardiol. 1993;72:314 323. 302. Carpenter JL. Perivalvular extension of infection in patients with infec- tious endocarditis. Rev Infect Dis. 1991;13:127 138. 303. Anguera I, Miro JM, Vilacosta I, Almirante B, Anguita M, Mu oz P, Roman JA, de Alarcon A, Ripoll T, Navas E, Gonzalez-Juanatey C, Cabell CH, Sarria C, Garcia-Bolao I, Fari as MC, Leta R, Rufi G, Miralles F, Pare C, Evangelista A, Fowler VG Jr, Mestres CA, de Lazzari E, Guma JR; Aorto-cavitary Fistula in Endocarditis Working Group. Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J. 2005;26:288 297. doi: 10.1093/eurheartj/ehi034. 304. Daniel W, Schroder E, Nonast-Daniel B, Lichtlen P. Conventional and transoesophageal echocardiography in the diagnosis of infective endo- carditis. Eur Heart J. 1987;8:287 292. 305. Leung DY, Cranney GB, Hopkins AP, Walsh WF. Role of transoesopha- geal echocardiography in the diagnosis and management of aortic root abscess. Br Heart J. 1994;72:175 181. 306. Rohmann S, Seifert T, Erbel R, Jakob H, Mohr-Kahaly S, Makowski T, G rge G, Oelert H, Meyer J. Identification of abscess formation in native-valve infective endocarditis using transesophageal echocardiog- raphy: implications for surgical treatment. Thorac Cardiovasc Surg. 1991;39:273 280. doi: 10.1055/s-2007-1019985. 307. Kunis RL, Sherrid MV, McCabe JB, Grieco MH, Dwyer EM Jr. Successful medical therapy of mitral anular abscess complicating infec- tive endocarditis. J Am Coll Cardiol. 1986;7:953 955. 308. Vlessis AA, Hovaguimian H, Jaggers J, Ahmad A, Starr A. Infective endocarditis: ten-year review of medical and surgical therapy. Ann Thorac Surg. 1996;61:1217 1222. 309.


Vlessis AA, Hovaguimian H, Jaggers J, Ahmad A, Starr A. Infective endocarditis: ten-year review of medical and surgical therapy. Ann Thorac Surg. 1996;61:1217 1222. 309. Mullany CJ, Chua YL, Schaff HV, Steckelberg JM, Ilstrup DM, Orszulak TA, Danielson GK, Puga FJ. Early and late survival after sur- gical treatment of culture-positive active endocarditis. Mayo Clin Proc. 1995;70:517 525. doi: 10.1016/S0025-6196(11)64307-3. 310. Glazier JJ, Verwilghen J, Donaldson RM, Ross DN. Treatment of complicated prosthetic aortic valve endocarditis with annular abscess formation by homograft aortic root replacement. J Am Coll Cardiol. 1991;17:1177 1182. 311. Ross D. Allograft root replacement for prosthetic endocarditis. J Card Surg. 1990;5:68 72. 312. McGiffin DC, Galbraith AJ, McLachlan GJ, Stower RE, Wong ML, Stafford EG, Gardner MA, Pohlner PG, O Brien MF. Aortic valve infec- tion: risk factors for death and recurrent endocarditis after aortic valve replacement. J Thorac Cardiovasc Surg. 1992;104:511 520. 313. Walkes JC, Reardon MJ. Current thinking in stentless valve surgery. Curr Opin Cardiol. 2003;18:117 123. 314. Chun CH, Raff MJ, Contreras L, Varghese R, Waterman N, Daffner R, Melo JC. Splenic abscess. Medicine (Baltimore). 1980;59:50 65. 315. Bohmfalk GL, Story JL, Wissinger JP, Brown WE Jr. Bacterial intracra- nial aneurysm. J Neurosurg. 1978;48:369 382. 316. WilsonWR, Giuliani ER, Danielson GK, Geraci JE. Management of com- plications of infective endocarditis. Mayo Clin Proc. 1982;57:162 170. 317. Camarata PJ, Latchaw RE, R fenacht DA, Heros RC. Intracranial aneu- rysms. Invest Radiol. 1993;28:373 382. 318. Lerner PI. Neurologic complications of infective endocarditis. Med Clin North Am. 1985;69:385 398. 319. Clare CE, Barrow DL. Infectious intracranial aneurysms. Neurosurg Clin N Am. 1992;3:551 566. 320. Moskowitz MA, Rosenbaum AE, Tyler HR. Angiographically monitored resolution of cerebral mycotic aneurysms. Neurology. 1974;24:1103 1108. 321. Huston J 3rd, Nichols DA, Luetmer PH, Goodwin JT, Meyer FB, Wiebers DO, Weaver AL.


Huston J 3rd, Nichols DA, Luetmer PH, Goodwin JT, Meyer FB, Wiebers DO, Weaver AL. Blinded prospective evaluation of sensitivity of MR angiography to known intracranial aneurysms: importance of aneurysm size. AJNR Am J Neuroradiol. 1994;15:1607 1614. 322. Wilson WR, Bower TC, Creager MA, Amin-Hanjani S, O Gara PT, Lockhart PB, Darouiche RO, Ramlawi B, Derdeyn CP, Bolger AF, Levison ME, Taubert KA, Baltimore RS, Baddour LM; on behalf of the American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia, Council on Peripheral Vascular Disease, and Stroke Council. Vascular graft infections, mycotic aneu- rysms, and endovascular infections: a scientific statement from the American Heart Association. Circulation. In press. 323. Tice AD. Safety of outpatient parenteral antimicrobial therapy for endo- carditis. Clin Infect Dis. 2002;34:419 420. doi: 10.1086/324369. 324. Monteiro CA, Cobbs CG. Outpatient management of infective endocar- ditis. Curr Infect Dis Rep. 2001;3:319 327. 325. Tice AD, Rehm SJ, Dalovisio JR, Bradley JS, Martinelli LP, Graham DR, Gainer RB, Kunkel MJ, Yancey RW, Williams DN; IDSA. Practice guidelines for outpatient parenteral antimicrobial therapy: IDSA guidelines. Clin Infect Dis. 2004;38:1651 1672. doi: 10.1086/420939. 326. Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infec- tive endocarditis. Clin Infect Dis. 2001;33:203 209. doi: 10.1086/321814. 327. Lockhart PB, Brennan MT, Thornhill M, Michalowicz BS, Noll J, Bahrani-Mougeot FK, Sasser HC. Poor oral hygiene as a risk fac- tor for infective endocarditis-related bacteremia. J Am Dent Assoc. 2009;140:1238 1244. 328. Lockhart PB. Antibiotic prophylaxis for dental procedures: are we drilling in the wrong direction? Circulation. 2012;126:11 12. doi: 10.1161/CIRCULATIONAHA.112.115204.


*ACC/AHA Representative. Lay Representative. ACC/AHA Task Force on Clinical Practice Guidelines Liaison. Task Force Performance Measures Representative. The American Heart Association requests that this document be cited as follows: Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Mu oz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596 e646.


2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596 e646. DOI: 10.1161/ WRITING COMMITTEE MEMBERS Donna K. Arnett, PhD, MSPH, FAHA, Co-Chair Roger S. Blumenthal, MD, FACC, FAHA, Co-Chair Michelle A. Albert, MD, MPH, FAHA* Andrew B. Buroker, Esq Zachary D. Goldberger, MD, MS, FACC, FAHA Ellen J. Hahn, PhD, RN* Cheryl Dennison Himmelfarb, PhD, RN, ANP, FAHA* Amit Khera, MD, MSc, FACC, FAHA* Donald Lloyd-Jones, MD, SCM, FACC, FAHA* J. William McEvoy, MBBCh, MEd, MHS* Erin D. Michos, MD, MHS, FACC, FAHA* Michael D. Miedema, MD, MPH* Daniel Mu oz, MD, MPA, FACC* Sidney C. Smith Jr, MD, MACC, FAHA* Salim S. Virani, MD, PhD, FACC, FAHA* Kim A. Williams Sr, MD, MACC, FAHA* Joseph Yeboah, MD, MS, FACC, FAHA* Boback Ziaeian, MD, PhD, FACC, FAHA 2019 by the American College of Cardiology Foundation and the American Heart Association, Inc. ACC/AHA CLINICAL PRACTICE GUIDELINE 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Circulation https://www.ahajournals.org/journal/circ ACC/AHA Task Force Members, see page e623 Endorsed by the American Associa- tion of Cardiovascular and Pulmo- nary Rehabilitation, the American Geriatrics Society, the American Society of Preventive Cardiology, and the Preventive Cardiovascular Nurses Association Key Words: AHA Scientific Statements guidelines antihypertensive agents aspirin atherosclerosis atherosclerotic cardiovascular disease atrial fibrillation behavior modification behavior therapy blood cholesterol blood pressure body mass index cardiovascular team-based care cardiovascular cardiovascular disease cholesterol chronic kidney disease coronary artery calcium score coronary disease coronary heart disease cost diet dietary patterns dietary fats dietary sodium dyslipidemia e-cigarettes exercise healthcare disparities health services accessibility heart failure hypertension LDL cholesterol diabetes mellitus lifestyle lipids measurement myocardial infarction nicotine nonpharmacological treatment nutrition physical activity prejudice primary prevention psychosocial deprivation public health quality indicators quality measurement risk assessment risk-enhancing factors risk factors risk reduction risk reduction discussion risk treatment discussion secondhand smoke sleep smoking smoking cessation social determinants of health socioeconomic factors statin therapy systems of care tobacco tobacco smoke pollution treatment adherence treatment outcomes type 2 diabetes mellitus waist circumference weight loss CLINICAL STATEMENTS AND GUIDELINES TABLE OF CONTENTS Top 10 Take-Home Messages for the Primary Prevention of Cardiovascular Disease e597 Preamble e597 1.


Introduction e598 1.1. Methodology and Evidence Review e599 1.2. Organization of the Writing Committee e599 1.3. Document Review and Approval e599 1.4. Scope of the Guideline e599 1.5. Class of Recommendation and Level of Evidence e600 1.6. Abbreviations e601 2. Overarching Recommendations for ASCVD Prevention Efforts e601 2.1. Patient-Centered Approaches to Comprehensive ASCVD Prevention e601 2.2. Assessment of Cardiovascular Risk e602 3. Lifestyle Factors Affecting Cardiovascular Risk e605 3.1. Nutrition and Diet e605 3.2. Exercise and Physical Activity e607 4. Other Factors Affecting Cardiovascular Risk e609 4.1. Adults With Overweight and Obesity e609 4.2. Adults With Type 2 Diabetes Mellitus e610 4.3. Adults With High Blood Cholesterol e612 4.4. Adults With High Blood Pressure or Hypertension e616 4.5. Treatment of Tobacco Use e618 4.6. Aspirin Use e621 5. Cost and Value Considerations e622 6. Conclusion e623 Appendix 1: Search Criteria e636 Appendix 2: Author Relationships With Industry and Other Entities (Relevant) e641 Appendix 3: Reviewer Relationships With Industry and Other Entities (Comprehensive) e642 References e624 TOP 10 TAKE-HOME MESSAGES FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE 1. The most important way to prevent atherosclerotic vascular disease, heart failure, and atrial fibrillation is to promote a healthy lifestyle throughout life. 2. A team-based care approach is an effective strat- egy for the prevention of cardiovascular disease. Clinicians should evaluate the social determinants of health that affect individuals to inform treat- ment decisions. 3. Adults who are 40 to 75 years of age and are being evaluated for cardiovascular disease prevention should undergo 10-year atherosclerotic cardio- vascular disease (ASCVD) risk estimation and have a clinician patient risk discussion before starting on pharmacological therapy, such as antihyper- tensive therapy, a statin, or aspirin.


Adults who are 40 to 75 years of age and are being evaluated for cardiovascular disease prevention should undergo 10-year atherosclerotic cardio- vascular disease (ASCVD) risk estimation and have a clinician patient risk discussion before starting on pharmacological therapy, such as antihyper- tensive therapy, a statin, or aspirin. In addition, assessing for other risk-enhancing factors can help guide decisions about preventive interventions in select individuals, as can coronary artery calcium scanning. 4. All adults should consume a healthy diet that emphasizes the intake of vegetables, fruits, nuts, whole grains, lean vegetable or animal protein, and fish and minimizes the intake of trans fats, red meat and processed red meats, refined carbohy- drates, and sweetened beverages. For adults with overweight and obesity, counseling and caloric restriction are recommended for achieving and maintaining weight loss. 5. Adults should engage in at least 150 minutes per week of accumulated moderate-intensity physical activity or 75 minutes per week of vigorous-inten- sity physical activity. 6. For adults with type 2 diabetes mellitus, lifestyle changes, such as improving dietary habits and achieving exercise recommendations, are crucial. If medication is indicated, metformin is first-line therapy, followed by consideration of a sodium- glucose cotransporter 2 inhibitor or a glucagon- like peptide-1 receptor agonist. 7. All adults should be assessed at every healthcare visit for tobacco use, and those who use tobacco should be assisted and strongly advised to quit. 8. Aspirin should be used infrequently in the routine primary prevention of ASCVD because of lack of net benefit. 9. Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low-density lipoprotein cholesterol levels ( 190 mg/dL), those with diabetes mellitus, who are 40 to 75 years of age, and those determined to be at sufficient ASCVD risk after a clinician patient risk discussion. 10.


Statin therapy is first-line treatment for primary prevention of ASCVD in patients with elevated low-density lipoprotein cholesterol levels ( 190 mg/dL), those with diabetes mellitus, who are 40 to 75 years of age, and those determined to be at sufficient ASCVD risk after a clinician patient risk discussion. 10. Nonpharmacological interventions are recom- mended for all adults with elevated blood pressure or hypertension. For those requiring pharmaco- logical therapy, the target blood pressure should generally be <130/80 mm Hg. PREAMBLE Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, which are based on systematic meth- ods to evaluate and classify evidence, provide a founda- tion for the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and publica- tion of clinical practice guidelines without commercial support, and members volunteer their time to the writ- ing and review efforts. Clinical practice guidelines provide recommenda- tions applicable to patients with or at risk of developing CLINICAL STATEMENTS AND GUIDELINES cardiovascular disease (CVD). The focus is on medical practice in the United States, but these guidelines are relevant to patients throughout the world. Although guidelines may be used to inform regulatory or payer decisions, the goals are to improve quality of care and align with patients interests. Guidelines are intended to define practices meeting the needs of patients in most but not all circumstances and should not replace clinical judgment. Recommendations for guideline-directed manage- ment and therapy, which encompasses clinical evalua- tion, diagnostic testing, and both pharmacological and procedural treatments, are effective only when adopted by both practitioners and patients.


Recommendations for guideline-directed manage- ment and therapy, which encompasses clinical evalua- tion, diagnostic testing, and both pharmacological and procedural treatments, are effective only when adopted by both practitioners and patients. Adherence to rec- ommendations can be enhanced by shared decision- making between clinicians and patients, with patient engagement in selecting interventions on the basis of individual values, preferences, and associated condi- tions and comorbidities. The ACC/AHA Task Force on Clinical Practice Guide- lines strives to ensure that the guideline writing com- mittee includes requisite expertise and is representative of the broader medical community by selecting experts from a broad array of backgrounds, representing dif- ferent geographic regions, sexes, races, ethnicities, intellectual perspectives/biases, and scopes of clinical practice. The ACC and AHA have rigorous policies and methods to ensure that documents are developed with- out bias or improper influence. The complete policy on relationships with industry and other entities (RWI) can be found online. Beginning in 2017, numerous modifications to the guidelines have been and continue to be implemented to make guidelines shorter and enhance user friendli- ness. Guidelines are written and presented in a modu- lar knowledge chunk format, in which each chunk in- cludes a table of recommendations, a brief synopsis, recommendation-specific supportive text and, when appropriate, flow diagrams or additional tables. Hyper- linked references are provided for each modular knowl- edge chunk to facilitate quick access and review. More structured guidelines including word limits ( tar- gets ) and a web guideline supplement for useful but noncritical tables and figures are 2 such changes. This Preamble is an abbreviated version, with the detailed version available online.


This Preamble is an abbreviated version, with the detailed version available online. Patrick T. O Gara, MD, MACC, FAHA Chair, ACC/AHA Task Force on Clinical Practice Guidelines Although there has been substantial improvement in atherosclerotic cardiovascular disease (ASCVD) out- comes in recent decades, ASCVD remains the leading cause of morbidity and mortality globally.S1-1 S1-3 In the United States, it is also the leading cause of death for people of most racial/ethnic groups, with an estimated cost of >$200 billion annually in healthcare services, medications, and lost productivity. Much of this is at- tributable to suboptimal implementation of preven- tion strategies and uncontrolled ASCVD risk factors in Most Americans who have had a myocardial infarc- tion (MI) had unfavorable levels of at least 1 cardiovas- cular risk factor before their ASCVD event.S1-4 the AHA defined a new model of ideal cardiovascular health, referred to as Life s Simple 7.S1-5 Clinicians will find the 2018 Journal of American College of Cardiol- ogy (JACC) Cardiovascular Health Promotion Series very helpful in approaching the various aspects of preven- tion with patients.S1-6 An increasing number of ideal cardiovascular health factors have been associated with a lower prevalence and incidence of ASCVD events, heart failure, atrial fibrillation, cancer, depression, and Therefore, moving individuals toward ideal cardiovascular health is critically important for prevention of many important health conditions. The ACC/AHA Task Force on Clinical Practice Guide- lines has commissioned this guideline to consolidate existing recommendations and various recent scientific statements, expert consensus documents, and clinical practice guidelines into a single guidance document fo- cused on the primary prevention of ASCVD.


The ACC/AHA Task Force on Clinical Practice Guide- lines has commissioned this guideline to consolidate existing recommendations and various recent scientific statements, expert consensus documents, and clinical practice guidelines into a single guidance document fo- cused on the primary prevention of ASCVD. However, this guideline also includes newly generated recom- mendations for aspirin use, exercise and physical activ- ity, and tobacco use, in addition to recommendations related to team-based care, shared decision-making, and assessment of social determinants of health, to cre- ate a comprehensive yet targeted ACC/AHA guideline on the prevention of ASCVD. This guideline has been formatted in the modular chunk format to facilitate readability and future updating. Prevention strategies occur at the population level but must also engage individual adults to slow the de- velopment of ASCVD. The most important way to pre- vent ASCVD is to promote a healthy lifestyle through- out life. Prevention strategies must include a strong focus on lifestyle optimization (improvements in diet, physical activity, and avoidance of tobacco use and ex- posure to secondhand smoke) to minimize the risk of future ASCVD events. A comprehensive patient-centered approach that addresses all aspects of a patient s lifestyle habits and estimated risk of a future ASCVD event is the first step in deciding on where there may be a need for pharmacotherapy. Even if a blood pressure (BP) reduc- ing medication, lipid-lowering medication, or diabe- tes medication is ultimately prescribed, lifestyle goals should be emphasized on a regular basis. Only when a person s risk is sufficiently high should medications to reduce ASCVD risk be considered as part of a shared CLINICAL STATEMENTS AND GUIDELINES decision-making process for optimal treatment. In sum- mary, clinicians and individuals should focus attention on living a healthy lifestyle by referring to these evi- dence-based recommendations to help prevent ASCVD.


In sum- mary, clinicians and individuals should focus attention on living a healthy lifestyle by referring to these evi- dence-based recommendations to help prevent ASCVD. 1.1. Methodology and Evidence Review This guideline continues the ACC and AHA effort to de- sign a comprehensive yet succinct compilation of practi- cal guidance for the primary prevention of ASCVD and to promote optimal dissemination of information by us- ing concise language and formatting. The recommen- dations listed in this guideline are evidence based and supported by an extensive evidence review. A search for literature derived from research involving human sub- jects, published in English, and indexed in Ovid MED- LINE, PubMed, Cochrane Library, National Institute for Health and Care Excellence (NICE), and other selected databases relevant to this guideline, was conducted be- tween May and July 2018. For specific search terms used and years searched per section, please see Appendix 1. Randomized controlled trials (RCTs), systematic re- views of RCTs, meta-analyses, and large, United States based, high-quality cohort studies, as well as observa- tional studies and systematic reviews of observational studies, were evaluated for their content on the preven- tion of ASCVD outcomes related to the following 9 topic areas: risk assessment, diet, exercise/physical activity, obesity and weight loss, type 2 diabetes mellitus (T2DM), blood cholesterol, hypertension, smoking cessation, and aspirin use. Previous ACC/AHA guidelines, as well as US Preventive Services Task Force (USPSTF) reviews and other guidance relevant to this guideline, were also assessed. The final evidence tables included in the Online Data Supplement summarize the evidence used to formulate recommendations. References selected and published in this document are representative and not all-inclusive. Avalere Health, a healthcare advisory services firm con- tracted by ACC/AHA, served as the document manager for this guideline to facilitate its development process.


Avalere Health, a healthcare advisory services firm con- tracted by ACC/AHA, served as the document manager for this guideline to facilitate its development process. As document manager, Avalere facilitated the deliberations of the Writing Committee and led the modified Delphi process for establishing the Class of Recommendation and the Level of Evidence. In parallel, an independent health data and epidemiology expert, Lee Ann Prebil, conducted a systematic evidence review for the key topic of exercise and physical activity and conducted targeted literature searches to support this document s discussion of patient- centered approaches, including team-based care, shared decision-making, and assessment of social determinants of health. A targeted literature search was also conducted for this guideline s cost and value considerations. These searches are available as downloadable Excel files. Recommendations and supportive text relevant to cardiovascular risk, blood cholesterol, and high BP were taken directly from 2 recently released ACC/ AHA guidelines, the 2017 Hypertension Clinical Prac- and the 2018 Cholesterol Clini- cal Practice Guideline,S1.1-2 and were adapted for the present guideline, which aims to provide an overview of the primary prevention of ASCVD among adults. Recommendations that were adapted from previous publications are noted in the recommendation tables, and both the original published recommendation and the adapted version are provided in the guideline. The results of these evidence reviews were evaluat- ed by the writing committee for incorporation into the present guideline. (See Table S1 in the Web Supplement for a list of relevant publications and statements used in support of the guideline s recommendations.) Each topic area was assigned a primary writer, as well as a primary, and sometimes secondary, reviewer. These assignments were based on areas of particular expertise of writing committee members.


These assignments were based on areas of particular expertise of writing committee members. All recommendations were fully reviewed and discussed among the full committee to allow for diverse perspectives and considerations for this guideline. Recommendations were then voted upon, with a modified Delphi process used to reach consensus. 1.2. Organization of the Writing Committee The writing committee consisted of clinicians, cardi- ologists, health services researchers, epidemiologists, internists, nurses, and a lay representative. The writing committee included representatives from the ACC and AHA. Appendix 2 of the present document lists writing committee members relevant RWI. For the purposes of full transparency, the writing committee members com- prehensive disclosure information is available online. 1.3. Document Review and Approval This document was reviewed by 5 official reviewers nominated by the ACC and AHA (1 reviewer from the ACC/AHA Task Force for Practice Guidelines, 2 review- ers from the AHA, and 2 reviewers from the ACC); 3 reviewers on behalf of the American Association of Car- diovascular and Pulmonary Rehabilitation, the American Society for Nutrition, and the American Society of Pre- ventive Medicine; and 23 individual content reviewers. Reviewers RWI information was distributed to the writ- ing committee and is published in this document (Ap- pendix 3). This document was approved for publication by the governing bodies of the ACC and AHA. 1.4. Scope of the Guideline This guideline is intended to be a resource for the clini- cal and public health practice communities. It addresses the primary prevention of CVD in adults ( 18 years of age), focused on outcomes of ASCVD (ie, acute coronary CLINICAL STATEMENTS AND GUIDELINES syndromes, MI, stable or unstable angina, arterial re- vascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin), as well as heart failure and atrial fibrillation.


It addresses the primary prevention of CVD in adults ( 18 years of age), focused on outcomes of ASCVD (ie, acute coronary CLINICAL STATEMENTS AND GUIDELINES syndromes, MI, stable or unstable angina, arterial re- vascularization, stroke, transient ischemic attack, or peripheral arterial disease of atherosclerotic origin), as well as heart failure and atrial fibrillation. The guide- line presents recommendations to prevent CVD that are related to lifestyle factors (eg, diet and exercise or physical activity), other factors affecting CVD risk (eg, obesity, diabetes, blood cholesterol, high BP, smoking, aspirin use), patient-centered approaches (eg, team- based care, shared decision-making, assessment of so- cial determinants of health), and considerations of the cost and value of primary prevention. 1.5. Class of Recommendation and Level of Evidence Recommendations are designated with both a Class of Recommendation (COR) and a Level of Evidence (LOE). The COR indicates the strength of recommen- dation, encompassing the estimated magnitude and certainty of benefit in proportion to risk. The LOE rates the quality of scientific evidence supporting the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table 1).S1.5-1 Table 1.


The LOE rates the quality of scientific evidence supporting the intervention on the basis of the type, quantity, and consistency of data from clinical trials and other sources (Table 1).S1.5-1 Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care (Updated August 2015) CLINICAL STATEMENTS AND GUIDELINES Abbreviation Meaning/Phrase ASCVD atherosclerotic cardiovascular disease AU Agatston units BMI body mass index BP blood pressure CHD coronary heart disease CKD chronic kidney disease CVD cardiovascular disease DASH Dietary Approaches to Stop Hypertension DBP diastolic blood pressure DM diabetes mellitus ENDS electronic nicotine delivery systems FDA US Food and Drug Administration HDL-C high-density lipoprotein cholesterol LDL-C low-density lipoprotein cholesterol MI myocardial infarction PCE pooled cohort equations RCT randomized controlled trial SBP systolic blood pressure T2DM type 2 diabetes mellitus USPSTF US Preventive Services Task Force 2. OVERARCHING RECOMMENDATIONS FOR ASCVD PREVENTION EFFORTS 2.1. Patient-Centered Approaches to Comprehensive ASCVD Prevention Recommendations for Patient-Centered Approaches to Comprehensive ASCVD Prevention Referenced studies that support recommendations are summarized in Online Data Supplements 1 and 2. COR LOE Recommendations I A A team-based care approach is recommended for the control of risk factors associated with ASCVD.S2.1-1 S2.1-14 I B-R Shared decision-making should guide discussions about the best strategies to reduce ASCVD risk.S2.1-15 S2.1-18 I B-NR Social determinants of health should inform optimal implementation of treatment recommendations for the prevention of Synopsis This 2019 ACC/AHA Guideline on the Primary Preven- tion of CVD aims to promote the delivery of patient- centered care, which the writing committee felt was foundational to the guidance provided throughout. These patient-centered recommendations emphasize the importance of team-based care delivery, shared decision-making, and the evaluation of social determi- nants of health in ASCVD prevention efforts.


These patient-centered recommendations emphasize the importance of team-based care delivery, shared decision-making, and the evaluation of social determi- nants of health in ASCVD prevention efforts. These rec- ommendations apply to all aspects of clinical practice for the primary prevention of ASCVD. Recommendation-Specific Supportive Text 1. Team-based care makes use of multidisciplinary health professionals to improve the quality and maintenance of ASCVD prevention. It is a multi- faceted approach that supports clinical decision- making (ie, treatment algorithms), collaboration among different clinicians, and patient and fam- ily member participation to facilitate the treat- ment goals of patients.S2.1-26 RCTs and systematic reviews with meta-analyses demonstrated greater reduction of ASCVD risk with team-based care than with usual care in patients with hyperten- sion, diabetes, and hyperlipidemia.S2.1-1 S2.1-14 A team-based approach to ASCVD prevention may result in significant improvements in patient out- and often meets patient needs bet- ter than standard care, especially in low-resource settings and among vulnerable populations. In a team-based care model that compared patients enrolled in a preventive cardiology clinic staffed by advanced practice providers with a propensity- matched cohort of patients enrolled in primary care clinics, a reduction in cardiovascular risk was demonstrated through effective risk stratification and preventive management.S2.1-28 Other success- ful interventions that have used team-based care include telehealth monitoring, follow-up support aids, and patient education.S2.1-27 2. Decisions about primary prevention should be collaborative between a clinician and a patient. Shared decision-making occurs when practitioners engage patients in discussions about personal- ized ASCVD risk estimates and their implications for the perceived benefits of preventive strate- gies, including lifestyle habits, goals, and medical therapies. Collaborative decisions are more likely to address potential barriers to treatment options, compared with treatment and guidance offered without patient input.S2.1-15 S2.1-18 3.


Collaborative decisions are more likely to address potential barriers to treatment options, compared with treatment and guidance offered without patient input.S2.1-15 S2.1-18 3. Socioeconomic inequalities are strong determinants of CVD risk internationally.S2.1-21,S2.1-24 Therefore, the clinician should tailor advice to a patient s socioeco- nomic and educational status, as well as cultural, work, and home environments.S2.1-23 The Centers for Medicare & Medicaid Services has developed a CLINICAL STATEMENTS AND GUIDELINES screening tool to assess 5 domains of non health- related measures that affect health outcomes: housing instability, food insecurity, transportation difficulties, utility assistance needs, and interper- ASCVD prevention could ben- efit from such screening. ASCVD risk begins early in life, with heightened susceptibility tied to low Examples of upstream social determinants of health that affect treatment adherence and ASCVD health outcomes include comorbid mental illness, lack of health literacy, exposure to adversity (eg, home/community vio- lence, trauma exposures, safety concerns), finan- cial strain, inadequate housing conditions, lack of food security (ie, access to affordable and nutritious food), and inadequate social support.S2.1-30 Systems of care should evaluate social determinants of health that affect care delivery for the primary pre- vention of ASCVD (eg, transportation barriers, the availability of health services). Important considerations related to socioeco- nomic disadvantage are not captured by existing CVD risk equations.S2.1-31 Addressing unmet social needs improves management of BP and lipids,S2.1-32 which highlights the importance of dietary coun- seling and encouraging physical activity.S2.1-19 More time may be required to address ASCVD preven- tion with adults of low health literacy or disadvan- taged educational backgrounds. Differential cardiovascular outcomes persist by important sociodemographic characteristics that include but are not limited to age, sex, and race/ Failure to address the impact of social determinants of health impedes efficacy of proven prevention recommendations.


Differential cardiovascular outcomes persist by important sociodemographic characteristics that include but are not limited to age, sex, and race/ Failure to address the impact of social determinants of health impedes efficacy of proven prevention recommendations. Table 2 outlines key considerations related to social determinants of health and ASCVD prevention. 2.2. Assessment of Cardiovascular Risk Recommendations for Assessment of Cardiovascular Risk Referenced studies that support recommendations are summarized in Online Data Supplement 3. COR LOE Recommendations I B-NR For adults 40 to 75 years of age, clinicians should routinely assess traditional cardiovascular risk factors and calculate 10-year risk of ASCVD by using the pooled cohort equations (PCE).S2.2-1,S2.2-2 IIa B-NR For adults 20 to 39 years of age, it is reasonable to assess traditional ASCVD risk factors at least every 4 to 6 years.S2.2-1 S2.2-3 IIa B-NR In adults at borderline risk (5% to <7.5% 10-year ASCVD risk) or intermediate risk ( 7.5% to <20% 10-year ASCVD risk), it is reasonable to use additional risk-enhancing factors to guide decisions about preventive interventions (eg, statin therapy).S2.2-4 S2.2-14 IIa B-NR In adults at intermediate risk ( 7.5% to <20% 10-year ASCVD risk) or selected adults at borderline risk (5% to <7.5% 10- year ASCVD risk), if risk-based decisions for preventive interventions (eg, statin therapy) remain uncertain, it is reasonable to measure a coronary artery calcium score to guide clinician patient risk discussion.S2.2-15 S2.2-31 Table 2.


COR LOE Recommendations I B-NR For adults 40 to 75 years of age, clinicians should routinely assess traditional cardiovascular risk factors and calculate 10-year risk of ASCVD by using the pooled cohort equations (PCE).S2.2-1,S2.2-2 IIa B-NR For adults 20 to 39 years of age, it is reasonable to assess traditional ASCVD risk factors at least every 4 to 6 years.S2.2-1 S2.2-3 IIa B-NR In adults at borderline risk (5% to <7.5% 10-year ASCVD risk) or intermediate risk ( 7.5% to <20% 10-year ASCVD risk), it is reasonable to use additional risk-enhancing factors to guide decisions about preventive interventions (eg, statin therapy).S2.2-4 S2.2-14 IIa B-NR In adults at intermediate risk ( 7.5% to <20% 10-year ASCVD risk) or selected adults at borderline risk (5% to <7.5% 10- year ASCVD risk), if risk-based decisions for preventive interventions (eg, statin therapy) remain uncertain, it is reasonable to measure a coronary artery calcium score to guide clinician patient risk discussion.S2.2-15 S2.2-31 Table 2. Example Considerations for Addressing Social Determinants of Health to Help Prevent ASCVD Events Topic/Domain Example Considerations Cardiovascular risk Adults should be routinely assessed for psychosocial stressors and provided with appropriate counseling.S2.1-31 Health literacy should be assessed every 4 to 6 y to maximize recommendation effectiveness.S2.1-36 Diet In addition to the prescription of diet modifications, body size perception, as well as social and cultural influences, should be Potential barriers to adhering to a heart-healthy diet should be assessed, including food access and economic factors; these factors may be particularly relevant to persons from vulnerable populations, such as individuals residing in either inner-city or rural environments, those at socioeconomic disadvantage, and those of advanced age*.S2.1-39 Exercise and physical activity In addition to the prescription of exercise, neighborhood environment and access to facilities for physical activity should be Obesity and weight loss Lifestyle counseling for weight loss should include assessment of and interventional recommendations for psychosocial stressors, sleep hygiene, and other individualized barriers.S2.1-42 S2.1-44 Weight maintenance should be promoted in patients with overweight/obesity who are unable to achieve recommended weight loss.


Example Considerations for Addressing Social Determinants of Health to Help Prevent ASCVD Events Topic/Domain Example Considerations Cardiovascular risk Adults should be routinely assessed for psychosocial stressors and provided with appropriate counseling.S2.1-31 Health literacy should be assessed every 4 to 6 y to maximize recommendation effectiveness.S2.1-36 Diet In addition to the prescription of diet modifications, body size perception, as well as social and cultural influences, should be Potential barriers to adhering to a heart-healthy diet should be assessed, including food access and economic factors; these factors may be particularly relevant to persons from vulnerable populations, such as individuals residing in either inner-city or rural environments, those at socioeconomic disadvantage, and those of advanced age*.S2.1-39 Exercise and physical activity In addition to the prescription of exercise, neighborhood environment and access to facilities for physical activity should be Obesity and weight loss Lifestyle counseling for weight loss should include assessment of and interventional recommendations for psychosocial stressors, sleep hygiene, and other individualized barriers.S2.1-42 S2.1-44 Weight maintenance should be promoted in patients with overweight/obesity who are unable to achieve recommended weight loss. Diabetes mellitus In addition to the prescription of type 2 diabetes mellitus interventions, environmental and psychosocial factors, including depression, stress, self-efficacy, and social support, should be assessed to improve achievement of glycemic control and adherence to treatment.S2.1-45 S2.1-48 High blood pressure Short sleep duration (<6 h) and poor-quality sleep are associated with high blood pressure and should be considered.S2.1-49 Because other lifestyle habits can impact blood pressure, access to a healthy, low-sodium diet and viable exercise options should also be considered. Tobacco treatment Social support is another potential determinant of tobacco use. Therefore, in adults who use tobacco, assistance and arrangement for individualized and group social support counseling are recommended.S2.1-50,S2.1-51 *Advanced age generally refers to age 75 years.


Therefore, in adults who use tobacco, assistance and arrangement for individualized and group social support counseling are recommended.S2.1-50,S2.1-51 *Advanced age generally refers to age 75 years. ASCVD indicates atherosclerotic cardiovascular disease. CLINICAL STATEMENTS AND GUIDELINES IIb B-NR For adults 20 to 39 years of age and for those 40 to 59 years of age who have <7.5% 10-year ASCVD risk, estimating lifetime or 30-year ASCVD risk may be Synopsis Assessment of ASCVD risk remains the foundation of primary prevention. Although all individuals should be encouraged to follow a heart-healthy lifestyle, estimat- ing an individual s 10-year absolute ASCVD risk enables matching the intensity of preventive interventions to the patient s absolute risk, to maximize anticipated benefit and minimize potential harm from overtreatment. The 10-year ASCVD risk estimate is used to guide decision- making for many preventive interventions, including and BP management;S2.2-37 it should be the start of a conversation with the pa- tient about risk-reducing strategies (the clinician pa- tient discussion ) and not the sole decision factor for the initiation of pharmacotherapy.S2.2-4,S2.2-36,S2.2-38 All risk estimation tools have inherent limitations, and pop- ulation-based risk scores must be interpreted in light of specific circumstances for individual patients. The PCE have been shown to overestimateS2.2-15,S2.2-39 S2.2-47 ASCVD risk for cer- tain subgroups. Thus, after calculation of the PCE, it is reasonable to use additional risk-enhancing factors to guide decisions about preventive interventions for bor- derline- or intermediate-risk adults.S2.2-4 S2.2-14 However, the value of preventive therapy may remain uncertain for many individuals with borderline or intermediate es- timated 10-year risk, and some patients may be reluc- tant to take medical therapy without clearer evidence of increased ASCVD risk.


Thus, after calculation of the PCE, it is reasonable to use additional risk-enhancing factors to guide decisions about preventive interventions for bor- derline- or intermediate-risk adults.S2.2-4 S2.2-14 However, the value of preventive therapy may remain uncertain for many individuals with borderline or intermediate es- timated 10-year risk, and some patients may be reluc- tant to take medical therapy without clearer evidence of increased ASCVD risk. For these individuals, the as- sessment of coronary artery calcium is a reasonable tool to reclassify risk either upward or downward, as part of shared decision-making. For younger adults 20 to 59 years of age, estimation of lifetime risk may be considered. For adults >75 years of age, the clinician and patient should engage in a discussion about the possible benefits of preventive therapies appropriate to the age group in the context of comorbidities and life expectancy. Recommendation-Specific Supportive Text 1. To facilitate decisions about preventive interven- tions, it is recommended to screen for traditional ASCVD risk factors and apply the race- and sex- specific PCE (ASCVD Risk Estimator) to estimate 10-year ASCVD risk for asymptomatic adults 40 to For management of stage 1 hypertension (BP 130 139 / 80 89 mm Hg), adults should be categorized as <10% or >10% 10-year ASCVD risk for therapeutic decisions (see Section 4.4 Figure 4). For management of blood cholesterol, adults should be categorized as having The PCE are best validated among non- Hispanic whites and non-Hispanic blacks living in the United States.S2.2-1,S2.2-39,S2.2-48,S2.2-49,S2.2-52 In other or in some non- the PCE may overestimate or underestimate risk. Therefore, clinicians may consider the use of another risk prediction tool as an alternative to the PCE if the tool was validated in a population with charac- teristics similar to those of the evaluated patient.


Therefore, clinicians may consider the use of another risk prediction tool as an alternative to the PCE if the tool was validated in a population with charac- teristics similar to those of the evaluated patient. Examples include the general Framingham CVD the Reynolds risk scores,S2.2-56,S2.2-57 SCORE (Systematic COronary Risk Evaluation),S2.2-58 and the QRISK/JBS3S2.2-59 tools. Other professional societies have incorporated some of these alterna- tive validated risk scores into their lipid manage- ment guidelines or have considered different risk thresholds for preventive interventions.S2.2-58 S2.2-63 Although slight differences exist across organi- zational guidelines, they are all very similar in their overarching goal of matching the intensity of preventive therapies to the absolute (generally 10-year) risk of the patient.S2.2-58 S2.2-63 2. After age 20 years, it is reasonable to mea- sure traditional risk factors at least every 4 to For adults 20 to 39 years of age, limited data exist on the performance and utility of Because age is a major driver of risk, most in this age range (<40 years) are unlikely to have a sufficiently elevated 10-year risk to warrant pharmacological therapy with a statin (with some exceptions, such as in familial hypercholesterolemia). Nevertheless, peri- odic assessment of risk factors (eg, at least every 4 to 6 years in younger adults 20 to 39 years of age) is important to guide discussions about inten- sity of lifestyle interventions, frequency of risk factor monitoring, treatment of nonlipid risk fac- tors, and consideration of 30-year or lifetime risk 3. No single risk calculator is appropriate for all patients.


Nevertheless, peri- odic assessment of risk factors (eg, at least every 4 to 6 years in younger adults 20 to 39 years of age) is important to guide discussions about inten- sity of lifestyle interventions, frequency of risk factor monitoring, treatment of nonlipid risk fac- tors, and consideration of 30-year or lifetime risk 3. No single risk calculator is appropriate for all patients. In certain populations, the PCE have However, some studies have found underestimation of risk (and potential for undertreatment) among indi- viduals with chronic inflammatory conditions (eg, ) or not Recommendations for Assessment of Cardiovascular Risk (Continued) COR LOE Recommendations CLINICAL STATEMENTS AND GUIDELINES captured in current risk scoring models. Patients with familial hypercholesterolemia are at signifi- cant risk of having an early ASCVD event, and the use of risk calculators is not applicable to these patients.


Patients with familial hypercholesterolemia are at signifi- cant risk of having an early ASCVD event, and the use of risk calculators is not applicable to these patients. In contrast, other studies have found overestimation of risk with the PCE, particularly among those with higher socioeconomic posi- tion and those with continual access to care and preventive services, which could lead to overtreat- ment of individuals less likely to receive net benefit from preventive pharmacotherapies over the next The PCE may be subopti- mally calibrated in more modern populations as compared with the older cohorts from which they Therefore, among adults at bor- derline (5% to <7.5%) and intermediate ( 7.5% to <20%) risk, one may consider additional individual risk-enhancing clinical factors (Table 3) that can be used to revise the 10-year ASCVD risk estimate.S2.2-4 These factors may include having a family history of premature ASCVD,S2.2-5 chronic inflammatory disease [rheumatoid arthritis,S2.2-6 or HIV ], South Asian ancestry,S2.2-13 a history or preterm delivery,S2.2-9 early chronic kidney disease (CKD), metabolic syndrome, per- sistently elevated inflammatory markers,S2.2-14 or elevated lipid biomarkers.S2.2-4 After these clini- cally available risk-enhancing factors have been considered, if there is still uncertainty about the reliability of the risk estimate for individu- als in the borderline- or intermediate-risk cat- egories, further testing to document subclinical coronary atherosclerosis is reasonable to more accurately reclassify the risk estimate upward or 4.


In contrast, other studies have found overestimation of risk with the PCE, particularly among those with higher socioeconomic posi- tion and those with continual access to care and preventive services, which could lead to overtreat- ment of individuals less likely to receive net benefit from preventive pharmacotherapies over the next The PCE may be subopti- mally calibrated in more modern populations as compared with the older cohorts from which they Therefore, among adults at bor- derline (5% to <7.5%) and intermediate ( 7.5% to <20%) risk, one may consider additional individual risk-enhancing clinical factors (Table 3) that can be used to revise the 10-year ASCVD risk estimate.S2.2-4 These factors may include having a family history of premature ASCVD,S2.2-5 chronic inflammatory disease [rheumatoid arthritis,S2.2-6 or HIV ], South Asian ancestry,S2.2-13 a history or preterm delivery,S2.2-9 early chronic kidney disease (CKD), metabolic syndrome, per- sistently elevated inflammatory markers,S2.2-14 or elevated lipid biomarkers.S2.2-4 After these clini- cally available risk-enhancing factors have been considered, if there is still uncertainty about the reliability of the risk estimate for individu- als in the borderline- or intermediate-risk cat- egories, further testing to document subclinical coronary atherosclerosis is reasonable to more accurately reclassify the risk estimate upward or 4. For individuals with intermediate predicted risk ( 7.5% to <20%) by the PCE or for select adults with borderline (5% to <7.5%) predicted risk, coronary artery calcium measurement can be a useful tool in refining risk assessment for preven- tive interventions (eg, statin therapy).S2.2-4 In these groups, coronary artery calcium measurement can reclassify risk upward (particularly if coronary artery calcium score is 100 Agatston units (AU) or 75th age/sex/race percentile) or downward (if coronary artery calcium is zero) in a signifi- cant proportion of individuals.S2.2-15 The extent of reclassification is sufficient to provide confidence that borderline- or intermediate-risk patients with elevated coronary artery calcium will have event rates that clearly exceed benefit thresholds (ie, 7.5% in 10 years) and those with coronary artery calcium scores of zero will have event rates <7.5%, which can help guide shared decision- making about statinsS2.2-15,S2.2-16,S2.2-21 or potentially In observational data, the pres- ence and severity of coronary artery calcium have Table 3.


For individuals with intermediate predicted risk ( 7.5% to <20%) by the PCE or for select adults with borderline (5% to <7.5%) predicted risk, coronary artery calcium measurement can be a useful tool in refining risk assessment for preven- tive interventions (eg, statin therapy).S2.2-4 In these groups, coronary artery calcium measurement can reclassify risk upward (particularly if coronary artery calcium score is 100 Agatston units (AU) or 75th age/sex/race percentile) or downward (if coronary artery calcium is zero) in a signifi- cant proportion of individuals.S2.2-15 The extent of reclassification is sufficient to provide confidence that borderline- or intermediate-risk patients with elevated coronary artery calcium will have event rates that clearly exceed benefit thresholds (ie, 7.5% in 10 years) and those with coronary artery calcium scores of zero will have event rates <7.5%, which can help guide shared decision- making about statinsS2.2-15,S2.2-16,S2.2-21 or potentially In observational data, the pres- ence and severity of coronary artery calcium have Table 3. Risk-Enhancing Factors for Clinician Patient Risk Discussion Risk-Enhancing Factors Family history of premature ASCVD (males, age <55 y; females, age <65 y) Primary hypercholesterolemia (LDL-C, 160 189 mg/dL [4.1 4.8 mmol/L]; non HDL-C 190 219 mg/dL [4.9 5.6 mmol/L])* Metabolic syndrome (increased waist circumference [by ethnically appropriate cutpoints], elevated triglycerides [>150 mg/dL, nonfasting], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 mg/dL in women] are factors; a tally of 3 makes the diagnosis) with or without albuminuria; not treated with dialysis or kidney transplantation) Chronic inflammatory conditions, such as psoriasis, RA, lupus, or HIV/AIDS History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that increase later ASCVD risk, such as preeclampsia High-risk race/ethnicity (eg, South Asian ancestry) Lipids/biomarkers: associated with increased ASCVD risk Persistently elevated* primary hypertriglyceridemia ( 175 mg/dL, nonfasting) If measured: Elevated high-sensitivity C-reactive protein ( 2.0 mg/L) Elevated Lp(a): A relative indication for its measurement is family history of premature ASCVD.


Risk-Enhancing Factors for Clinician Patient Risk Discussion Risk-Enhancing Factors Family history of premature ASCVD (males, age <55 y; females, age <65 y) Primary hypercholesterolemia (LDL-C, 160 189 mg/dL [4.1 4.8 mmol/L]; non HDL-C 190 219 mg/dL [4.9 5.6 mmol/L])* Metabolic syndrome (increased waist circumference [by ethnically appropriate cutpoints], elevated triglycerides [>150 mg/dL, nonfasting], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 mg/dL in women] are factors; a tally of 3 makes the diagnosis) with or without albuminuria; not treated with dialysis or kidney transplantation) Chronic inflammatory conditions, such as psoriasis, RA, lupus, or HIV/AIDS History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that increase later ASCVD risk, such as preeclampsia High-risk race/ethnicity (eg, South Asian ancestry) Lipids/biomarkers: associated with increased ASCVD risk Persistently elevated* primary hypertriglyceridemia ( 175 mg/dL, nonfasting) If measured: Elevated high-sensitivity C-reactive protein ( 2.0 mg/L) Elevated Lp(a): A relative indication for its measurement is family history of premature ASCVD. An Lp(a) 50 mg/dL or 125 nmol/L constitutes a risk- enhancing factor, especially at higher levels of Lp(a). Elevated apoB ( 130 mg/dL): A relative indication for its measurement would be triglyceride 200 mg/dL. A level 130 mg/dL corresponds to an LDL-C >160 mg/dL and constitutes a risk-enhancing factor *Optimally, 3 determinations. ABI indicates ankle-brachial index; AIDS, acquired immunodeficiency syndrome; apoB, apolipoprotein B; ASCVD, atherosclerotic cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein (a); and RA, rheumatoid arthritis. Reproduced with permission from Grundy et al.S2.2-4 Copyright 2018, American Heart Association, Inc., and American College of Cardiology Foundation.


Reproduced with permission from Grundy et al.S2.2-4 Copyright 2018, American Heart Association, Inc., and American College of Cardiology Foundation. CLINICAL STATEMENTS AND GUIDELINES been shown to be associated with the likelihood of benefit from statin therapy for ASCVD risk Coronary artery calcium scoring has superior discrimination and risk reclassification as compared with other subclinical imaging mark- ers or biomarkers.S2.2-22,S2.2-27 In the MESA (Multi- Ethnic Study of Atherosclerosis) trial, the coronary artery calcium score was strongly associated with 10-year ASCVD risk in a graded manner across age, sex, and racial/ethnic groups, independent of traditional risk factors.S2.2-17 Coronary artery cal- cium may even refine ASCVD risk estimates among younger adults (<45 years of age),S2.2-20 and older adults ( 75 years of age),S2.2-26 but more data are needed to support its use in these subgroups. A coronary artery calcium score of zero identifies indi- viduals at lower risk of ASCVD events and death who appear to derive little or no benefit from statins for ASCVD Thus, the absence of coronary artery calcium could reclassify a patient downward into a lower risk group in which preventive interven- tions (eg, statins) could be postponed.S2.2-22 Note that the absence of coronary artery calcium does not rule out noncalcified plaque, and clinical judg- ment about risk should prevail. Coronary artery cal- cium might also be considered in refining risk for selected low-risk adults (<5% 10-year risk), such as those with a strong family history of premature coronary heart disease (CHD).S2.2-23 and Astro-CHARM (Astronaut Cardiovascular Health and Risk Modification)S2.2-29 are risk estimation tools that incorporate both risk factors and coronary artery calcium for estimating 10-year CHD and ASCVD risk, respectively.


Coronary artery cal- cium might also be considered in refining risk for selected low-risk adults (<5% 10-year risk), such as those with a strong family history of premature coronary heart disease (CHD).S2.2-23 and Astro-CHARM (Astronaut Cardiovascular Health and Risk Modification)S2.2-29 are risk estimation tools that incorporate both risk factors and coronary artery calcium for estimating 10-year CHD and ASCVD risk, respectively. Coronary artery calcium measurement is not intended as a screening test for all but rather may be used as a decision aid in select adults to facilitate the clinician patient risk discussion. 5. For adults 20 to 39 years of age (who are not included in the PCE) and those 40 to 59 years of age who are not already at elevated ( 7.5%) 10-year risk, estimating a lifetime or 30-year risk of ASCVD may be considered (ASCVD Risk Younger individuals often have low estimated 10-year risk, but the presence of at least 1 major risk factor by middle age is associated with increased lifetime ASCVD risk and reduced survival free of morbidity compared with those with opti- mal risk factors.S2.2-32 S2.2-34 Calculation of lifetime risk with the ACC/AHA 30-year/lifetime risk esti- mator for those 20 to 59 years of age (not at high short-term risk) may be reasonable to consider as a communication strategy for reinforcing adher- ence to lifestyle recommendations.S2.2-2 3. LIFESTYLE FACTORS AFFECTING CARDIOVASCULAR RISK 3.1. Nutrition and Diet Recommendations for Nutrition and Diet Referenced studies that support recommendations are summarized in Online Data Supplements 4 and 5.


Nutrition and Diet Recommendations for Nutrition and Diet Referenced studies that support recommendations are summarized in Online Data Supplements 4 and 5. COR LOE Recommendations I B-R A diet emphasizing intake of vegetables, fruits, legumes, nuts, whole grains, and fish is recommended to decrease ASCVD risk IIa B-NR Replacement of saturated fat with dietary monounsaturated and polyunsaturated fats can be beneficial to reduce ASCVD IIa B-NR A diet containing reduced amounts of cholesterol and sodium can be beneficial to decrease ASCVD risk.S3.1-9,S3.1-14 S3.1-16 IIa B-NR As a part of a healthy diet, it is reasonable to minimize the intake of processed meats, refined carbohydrates, and sweetened beverages to reduce ASCVD risk.S3.1-17 S3.1-24 III: Harm B-NR As a part of a healthy diet, the intake of trans fats should be avoided to reduce Synopsis Approximately 630000 Americans died from heart dis- ease in 2015, of whom 366000 died from coronary ar- tery disease. After 4 decades of decline, heart disease deaths rose in 2015 by 1%.S3.1-28 This trend has been attributed to the obesity epidemic. Healthy nutrition has an important impact on ASCVD and its risk factors (see recommendations in the individual sections), po- tentially reversing or reducing obesity, high cholesterol, diabetes, and hypertension. The cardiovascular nutri- tion literature is limited by the paucity of large-scale prospective randomized trials with ASCVD outcomes. Although RCTs focused on hard endpoints are limited, multiple observational studies have focused on the association of CVD mortality with dietary patterns specifically, sugar, low-calorie sweeteners, high-carbo- hydrate diets, low-carbohydrate diets, refined grains, trans fat, saturated fat, sodium, red meat, and pro- cessed red meat (eg, bacon, salami, ham, hot dogs, Processed meats are any meat pre- served by smoking, curing, or salting, or additional Recommendation-Specific Supportive Text 1.


Although RCTs focused on hard endpoints are limited, multiple observational studies have focused on the association of CVD mortality with dietary patterns specifically, sugar, low-calorie sweeteners, high-carbo- hydrate diets, low-carbohydrate diets, refined grains, trans fat, saturated fat, sodium, red meat, and pro- cessed red meat (eg, bacon, salami, ham, hot dogs, Processed meats are any meat pre- served by smoking, curing, or salting, or additional Recommendation-Specific Supportive Text 1. Plant-based and Mediterranean diets, along with increased fruit, nut, vegetable, legume, and lean vegetable or animal protein (preferably fish) con- sumption, with the inherent soluble and insoluble CLINICAL STATEMENTS AND GUIDELINES vegetable fiber, have consistently been associated with lower risk of all-cause mortality than control or standard dietsS3.1-1 S3.1-10,S3.1-29,S3.1-30 in observa- tional studies. The PREDIMED (Prevenci n con Dieta Mediterr nea) trial randomized participants to a Mediterranean diet supplemented with either extra-virgin olive oil or nuts and demonstrated 30% and 28% reductions, respectively, in the combined endpoint (MI, stroke, or cardiovascular mortality), but the improved outcome was driven largely by the reduction in stroke, with no signifi- cant improvement over the control diet for mor- tality or MI.S3.1-1 When the PREDIMED cohort was reanalyzed post hoc for the provegetarian food pattern (more vegetable consumption versus ani- mal, egg, fish, dairy, or meat product consump- tion), a significant mortality rate reduction (41%) was noted in the 2 quintiles with the highest A comparison of plant and animal protein from the Adventist Health Study-2 similarly indicated that using meat for protein was associated with a 61% increase in mortality rate, whereas replacing meat with nuts and seeds was associated with a 40% reduction in mortality rate. Similarly, the graded risk published by Song et al.


The PREDIMED (Prevenci n con Dieta Mediterr nea) trial randomized participants to a Mediterranean diet supplemented with either extra-virgin olive oil or nuts and demonstrated 30% and 28% reductions, respectively, in the combined endpoint (MI, stroke, or cardiovascular mortality), but the improved outcome was driven largely by the reduction in stroke, with no signifi- cant improvement over the control diet for mor- tality or MI.S3.1-1 When the PREDIMED cohort was reanalyzed post hoc for the provegetarian food pattern (more vegetable consumption versus ani- mal, egg, fish, dairy, or meat product consump- tion), a significant mortality rate reduction (41%) was noted in the 2 quintiles with the highest A comparison of plant and animal protein from the Adventist Health Study-2 similarly indicated that using meat for protein was associated with a 61% increase in mortality rate, whereas replacing meat with nuts and seeds was associated with a 40% reduction in mortality rate. Similarly, the graded risk published by Song et al. indicated that lower mortality rate was associated with replacing animal protein of different origins with plant protein.S3.1-9 The evi- dence is mixed with regard to the effectiveness of dairy intake to reduce ASCVD risk factors, which is why it is not included in the listed foods for this recommendation. Although the DASH (Dietary Approaches to Stop Hypertension) diet, which includes low-fat dairy products, was shown to and the PURE (Prospective Urban Rural Epidemiology) study indicated that dairy intake was associated with a 23% lower mortality Song et al. indicated an 11% increase in cardiovascular mortality rate with dairy consump- tion as compared with vegetable protein S3.1-9). 2.


indicated an 11% increase in cardiovascular mortality rate with dairy consump- tion as compared with vegetable protein S3.1-9). 2. Trans and saturated fats have been associated with a higher risk of total and cause-specific death.S3.1-12 However, observational data from the PURE trial suggested that, when used instead of refined car- bohydrates, saturated and unsaturated fats were associated with reduced stroke and mortality.S3.1-13 3. Dietary sodium reduction was found to reduce BP and cardiovascular events in the DASH trial and in TOHP (Trials of Hypertension Prevention).S3.1-14,S3.1-15 Data from NHANES (National Health and Nutrition suggest that high con- sumption of sodium (>2000 mg daily), red meat (>14 g/d), and sugar-sweetened beverages and processed red meat consumption were associated with cardiovascular death. A prospective cohort study of US healthcare professionalsS3.1-9 with at least 1 risk factor indicated that replacement of animal protein (sources of cholesterol, saturated fat, heme iron and precursors of trimethylamine- N-oxide) with plant protein was associated with reduced cardiovascular mortality rate. In that study, compared with plant protein, poultry and fish were associated with a 6% higher mortality rate, dairy with an 8% higher mortality rate, unprocessed red meat with a 12% higher mortality rate, eggs with a 19% higher mortality rate, and processed red meat with a 34% higher mortality rate. Overall, plant protein was associated with a reduction in mortality rate of 10% for every 3% energy incre- ment replacement of animal protein. 4. Intake of several food products has been shown to be potentially harmful or increase risk of ASCVD.


Intake of several food products has been shown to be potentially harmful or increase risk of ASCVD. Sugar-sweetened and artificially sweetened bev- erages have been correlated with increasing the development of T2DM and with ASCVD risk, with a 20% increase in the frequency of diabetes mellitus with 1 daily serving of these sweetened In large cohort studies, consump- tion of added sugar at >10% of daily calories has been associated with increased mortality However, adults who are habitually high consumers of sugar-sweetened beverages and utilize low calorie sweetened beverages as a replacement strategy that provides a sweet taste while reducing caloric intake may find this use- ful in the transition to water.S3.1-20 In REGARDS (REasons for Geographic and Racial Differences the Southern dietary pattern was identified as substantially increasing health risks, including a 56% higher risk of heart disease and a 30% higher risk of stroke. This pattern con- sisted of more fried food, added fats, organ and processed meats, and sugar-sweetened bev- erages. Consuming a dietS3.1-4 with juices and sweetened beverages, refined grains, potatoes/ fries, and sweets resulted in a greater increase in coronary events than the increase seen with consumption of animal products. Given the addi- tional risk associated with intake of these various food products, clinicians would do well to coun- sel individuals about their associated harm and advise them to avoid these foods when possible. Furthermore, longstanding dietary patterns that focus on low intake of carbohydrates and a high intake of animal fat and protein are associated with increased cardiac and noncardiac mortal- low- carbohydrate diets were associated with a 31% higher risk of all-cause death, with increased cardiac mortality rate.


Furthermore, longstanding dietary patterns that focus on low intake of carbohydrates and a high intake of animal fat and protein are associated with increased cardiac and noncardiac mortal- low- carbohydrate diets were associated with a 31% higher risk of all-cause death, with increased cardiac mortality rate. Population data from the ARIC (Atherosclerosis Risk in Communities) study indicated an 18% increase in mortality rate with CLINICAL STATEMENTS AND GUIDELINES low-carbohydrate diets using animal-derived protein and fat sources (eg, lamb, beef, pork, but plant sources (eg, vegetables, nuts, peanut butter, whole-grain breads) were associated with lower mortality rate. In addition, the ARIC investigators noted a 23% increase in mortality rate associated with high-carbohydrate diets, with the optimal carbohydrate intake observed to be 50% to 55%. 5. Intake of trans fat has been shown to be harm- ful and increase risk of ASCVD. Trans fat was associated with higher all-cause mortality rate in the REGARDS US healthcare professionals cohort Additionally, regulations to curb use of trans fat in the food industry have been associated with a decrease in stroke and Trans fats have adverse effects on lipid and lipoproteins and promote endothelial dys- function, insulin resistance, inflammation, and Since partially hydrogenated oils are optional food additives, their elimination has been a public health priority.S3.1-27 3.2. Exercise and Physical Activity Recommendations for Exercise and Physical Activity Referenced studies that support recommendations are summarized in Online Data Supplements 6 and 7.


Exercise and Physical Activity Recommendations for Exercise and Physical Activity Referenced studies that support recommendations are summarized in Online Data Supplements 6 and 7. COR LOE Recommendations I B-R Adults should be routinely counseled in healthcare visits to optimize a physically I B-NR Adults should engage in at least 150 minutes per week of accumulated moderate-intensity or 75 minutes per week of vigorous-intensity aerobic physical activity (or an equivalent combination of moderate and vigorous activity) to reduce ASCVD IIa B-NR For adults unable to meet the minimum physical activity recommendations (at least 150 minutes per week of accumulated moderate-intensity or 75 minutes per week of vigorous-intensity aerobic physical activity), engaging in some moderate- or vigorous-intensity physical activity, even if less than this recommended amount, can be beneficial to reduce ASCVD risk.S3.2-5,S3.2-6 IIb C-LD Decreasing sedentary behavior in adults may be reasonable to reduce ASCVD Synopsis The numerous health benefits of regular physical activ- ity have been well established,S3.2-12 S3.2-15 and physical activity is a cornerstone of maintaining and improving Nevertheless, approximately half of adults in the United States do not meet the mini- mum physical activity recommendations.S3.2-12 Strategies are needed to increase physical activity at both the indi- vidual and the population levels.S3.2-16,S3.2-17 Extensive observational data from meta-analyses and systematic reviews support recommendations for aerobic physical activity to lower ASCVD risk.S3.2-3 S3.2-8, Resistance exercise should also be en- couraged because of its several health benefits, includ- ing improving physical functioning,S3.2-20 improving glycemic control in individuals with diabetes,S3.2-21 and possibly BP lowering.S3.2-22 Whether resistance exercise lowers ASCVD risk is unclear.S3.2-12 Aerobic physical activity is generally very safe.S3.2-23 However, sedentary individuals starting an exercise program should initiate exercise at a lower inten- sity (eg, slow walking) and duration and progress gradually to recommended levels.S3.2-24 It is uncertain whether an upper limit of habitual exercise, either in amount or intensity, may have adverse cardiovascular But, in discussions with patients, it should be mentioned that these very high levels of physical activity (ie, >10 times the minimum recom- mended amount) pertain to only a small fraction of the Individuals with significant functional impairments may need modifications to and more spe- cific guidance on the type, duration, and intensity of physical activity.


Recommendation-Specific Supportive Text 1. Physical activity assessment and counseling in the healthcare setting have important comple- mentary roles in promoting increased physical Ascertaining physical activity pat- terns during a standard clinical visit is the first step toward effective counseling and can be accomplished through several available simple The results of these tools can be recorded in the electronic health record, along with parameters such as weight and BP.S3.2-16 Physical activity counseling by clinicians can result in modest improvements in physical activity lev- els, with a number needed to counsel as low as 12 for an individual to achieve recommended physical activity levels.S3.2-1,S3.2-2 This counseling might include an exercise prescription that con- sists of recommended frequency, intensity, time (duration), and type of exercise. 2. There is a consistent, strong, inverse dose response relationship between the amount of moderate to vigorous physical activity and inci- dent ASCVD events and death.S3.2-3 S3.2-8,S3.2-12 The shape of the dose response relationship is curvilinear, with significant benefit observed when comparing those engaging in little or no physical activity with those performing moderate CLINICAL STATEMENTS AND GUIDELINES All adults should engage in at least 150 minutes per week of accumulated moderate-intensity aerobic physical activity or 75 minutes per week of vigorous-intensity aerobic physical activity (or an equivalent combination of moderate and vigorous activity) to lower ASCVD risk (Table 4). These recommendations are in line with those of other health organizations.S3.2-26 Shorter durations of exercise seem to be as ben- eficial as longer ones (eg, 10-minute bouts),S3.2- and thus the focus of physical activity counseling should be on the total accumulated amount.


These recommendations are in line with those of other health organizations.S3.2-26 Shorter durations of exercise seem to be as ben- eficial as longer ones (eg, 10-minute bouts),S3.2- and thus the focus of physical activity counseling should be on the total accumulated amount. Additional reduction in ASCVD risk is seen in those achieving higher amounts of aero- bic physical activity (>300 minutes per week of moderate-intensity aerobic physical activity or 150 minutes per week of vigorous-intensity aer- obic physical activity).S3.2-5,S3.2-6,S3.2-12,S3.2-14 There is a continued but diminishing additive benefit of further increasing physical activity to very high Specific exercise recommen- dations for the prevention of heart failure may differ slightly because the dose response rela- tionship with increasing physical activity levels may be linear.S3.2-29 3. There is likely no lower limit on the quantity of moderate-to-vigorous physical activity at which benefits for ASCVD risk start to accrue.S3.2-6 All efforts should be made to promote achievement of the minimum recommended amount of physi- cal activity by all adults. However, for individuals unable to achieve this minimum, encouraging at least some moderate-to-vigorous physical activity among those who are inactive (ie, no moderate- to-vigorous physical activity) or increasing the amount in those who are insufficiently active is still likely beneficial to reduce ASCVD risk.S3.2-6 Strategies to further increase physical activity in those achieving less than targeted amounts should be implemented. 4. Despite the focus on moderate- and vigorous- intensity physical activity, such activity accounts for a small proportion of individuals daily time as compared with other forms of activity. Other activity states that comprise a 24-hour period for an average individual include sleep, light-intensity physical activity, and sedentary behavior (Figure 1).


Other activity states that comprise a 24-hour period for an average individual include sleep, light-intensity physical activity, and sedentary behavior (Figure 1). Sedentary behavior refers to waking behavior with an energy expenditure of 1.5 metabolic equivalents while in a sitting or reclining posture (Table 4).S3.2-30 Increased sedentary behavior is associated with worse health parameters, including cardiometabolic risk Sedentary behavior may be most deleterious to ASCVD risk for individu- als who engage in the least amount of moder- ate to vigorous physical activity.S3.2-3,S3.2-10,S3.2-12 Thus, strategies to reduce sedentary behavior, particularly in those not achieving current rec- ommended physical activity levels, may be ben- eficial for lowering ASCVD risk. However, data on the value of reducing or modifying sedentary behavior over time to reduce ASCVD risk are sparse, and whether replacing sedentary behav- ior with light-intensity activity (eg, slow walking, light work) is beneficial for ASCVD prevention is The strength and specificity of the recommendation to reduce sedentary behavior are limited by uncertainty about the appropriate limits of and optimal approach to modifying sed- Figure 1. Hours per day spent in various states of activity. US adults spend >7 h/d on average in sedentary activities. Replacing sedentary time with other physical activity involves increasing either moderate- to vigorous-intensity physical activity or light-intensity physical activity. Data modified from Young et al.S3.2-30 Table 4.


Replacing sedentary time with other physical activity involves increasing either moderate- to vigorous-intensity physical activity or light-intensity physical activity. Data modified from Young et al.S3.2-30 Table 4. Definitions and Examples of Different Intensities of Physical Activity Intensity METs Examples Sedentary behavior* 1 1.5 Sitting, reclining, or lying; watching television Light 1.6 2.9 Walking slowly, cooking, light housework Moderate 3.0 5.9 Brisk walking (2.4 4 mph), biking (5 9 mph), ballroom dancing, active yoga, recreational swimming Vigorous 6 Jogging/running, biking ( 10 mph), singles tennis, swimming laps *Sedentary behavior is defined as any waking behavior characterized by an energy expenditure 1.5 METs while in a sitting, reclining, or lying posture. Standing is a sedentary activity in that it involves 1.5 METs, but it is not considered a component of sedentary behavior. MET indicates metabolic equivalent; and mph, miles per hour. CLINICAL STATEMENTS AND GUIDELINES 4. OTHER FACTORS AFFECTING CARDIOVASCULAR RISK 4.1. Adults With Overweight and Obesity Recommendations for Adults With Overweight and Obesity Referenced studies that support recommendations are summarized in Online Data Supplements 8 and 9. COR LOE Recommendations I B-R In individuals with overweight and obesity, weight loss is recommended to improve the ASCVD risk factor profile.0650 I B-R Counseling and comprehensive lifestyle interventions, including calorie restriction, are recommended for achieving and maintaining weight loss in adults with overweight and obesity.S4.1-1,S4.1-2 I C-EO Calculating body mass index (BMI) is recommended annually or more frequently to identify adults with overweight and obesity for weight loss considerations.


COR LOE Recommendations I B-R In individuals with overweight and obesity, weight loss is recommended to improve the ASCVD risk factor profile.0650 I B-R Counseling and comprehensive lifestyle interventions, including calorie restriction, are recommended for achieving and maintaining weight loss in adults with overweight and obesity.S4.1-1,S4.1-2 I C-EO Calculating body mass index (BMI) is recommended annually or more frequently to identify adults with overweight and obesity for weight loss considerations. IIa B-NR It is reasonable to measure waist circumference to identify those at higher Synopsis The increased availability of affordable, palatable, and high-calorie foods and the decreased physical de- mands of many jobs have fueled the epidemic of obe- sity and the consequent increases in hypertension and Adults diagnosed as obese (BMI 30 kg/m2 ) ) are at increased risk of ASCVD, heart failure, and atrial fibrillation, com- pared with those of a normal weight.S4.1-8,S4.1-9 The nu- tritional aspects of obesity revolve around the principle of balancing caloric intake with caloric expenditure. Following the 2013 Guideline for the Management of Overweight and Obesity in Adults from the AHA, ACC, and The Obesity Society (TOS), adults with overweight/ obesity are advised to participate in comprehensive life- style programs of 6 months duration that assist par- ticipants in adhering to a low-calorie diet (800 to 1500 kcal/day) and increased physical activity. Existing clinical guidance strongly recommends face-to-face or tele- phone-delivered weight-loss maintenance programs that provide regular contact (at least monthly) with a trained interventionist to help participants engage in high levels of physical activity (200 to 300 minutes/ week), monitor body weight regularly (at least weekly), and consume a reduced-calorie diet.S4.1-10 US Food and Drug Administration (FDA) approved and bariatric adjunctive to complementary lifestyle in- terventions, additionally reduce weight and may have a role in weight loss for select patients.